Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease

1998 ◽  
Vol 133 (4) ◽  
pp. 492-499 ◽  
Author(s):  
Eric A.F. Simoes ◽  
Henry M. Sondheimer ◽  
Franklin H. Top ◽  
H.Cody Meissner ◽  
Robert C. Welliver ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Respiratory Syncytial Virus ◽  
Immune Globulin ◽  
Congenital Heart ◽  
Virus Disease ◽  
Infants And Children ◽  
Respiratory Syncytial Virus Disease ◽  
Syncytial Virus ◽  
In Infants And Children

Junctional tachycardia in infants and children after open heart surgery for congenital heart disease

1987 ◽  
Vol 59 (12) ◽  
pp. 1216-1218 ◽  
Author(s):  
James W. Grant ◽  
Gerald A. Serwer ◽  
Brenda E. Armstrong ◽  
H.Newland Oldham ◽  
Page A.W. Anderson
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Heart Surgery ◽  
Open Heart Surgery ◽  
Infants And Children ◽  
Open Heart ◽  
Junctional Tachycardia ◽  
In Infants And Children

Respiratory Syncytial Virus Immune Globulin Intravenous

1997 ◽  
Vol 31 (1) ◽  
pp. 83-88 ◽  
Author(s):  
Todd L Wandstrat
Keyword(s):  
Clinical Trials ◽  
Respiratory Syncytial Virus ◽  
Immune Globulin ◽  
Data Extraction ◽  
Safety Data ◽  
Infants And Children ◽  
Medline Search ◽  
Study Selection ◽  
Syncytial Virus ◽  
In Infants And Children

OBJECTIVE: To review the clinical data detailing the use of respiratory syncytial virus immune globulin intravenous (RSV—IGIV) in infants and children. DATA SOURCES: A MEDLINE search (1990–1996) was used to identify all publications that dealt with RSV—IGIV clinical trials, pharmacology, and pharmacokinetics in infants and children. Bibliographies of articles were also used. STUDY SELECTION: All abstracts and clinical trials were reviewed. DATA EXTRACTION: Study design, population, efficacy, and safety data were retained. DATA SYNTHESIS: RSV—IGIV is an immunoglobulin product with serum neutralizing titers against RSV. It has been shown to reduce hospital stay, admissions, intensive care unit admissions, and mechanical ventilation days in infants and children with RSV pneumonia or bronchiolitis who are younger than 24 months of age and were born prematurely, or have bronchopulmonary dysplasia. RSV—IGIV is well tolerated by infants and children. CONCLUSIONS: RSV—IGIV is an effective prophylactic agent against serious RSV disease in select groups of infants and children.

scholarly journals 40 Respiratory syncytial virus-related outcomes from an abbreviated palivizumab dose regimen in children with congenital heart disease

2019 ◽  
Vol 24 (Supplement_2) ◽  
pp. e16-e17
Author(s):  
Pascal Lavoie ◽  
Jennifer Claydon ◽  
Constantin Popescu ◽  
Lana Shaibah ◽  
Cheryl Christopherson ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Respiratory Syncytial Virus ◽  
Dose Regimen ◽  
Congenital Heart ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document